Pulmonary Hypertension Due to Left Heart Disease Clinical Trial
Official title:
National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China
Left heart disease is the main cause of pulmonary hypertension. With the advent of the aging society, chronic heart failure has become a global public health problem. Therefore the prevalence of pulmonary hypertension due to the left heart disease is increasing. However, there is no research on the prevalence of pulmonary hypertension due to the left heart disease in China. Therefore, the aim of the present study was to describe real-world outcome of Chinese patients with pulmonary hypertension due to the left heart disease and identify factors that may predict outcome. Our study will profile the demographics, clinical course, treatments, and outcomes of pulmonary hypertension due to the left heart disease in China.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06048120 -
A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)
|
Phase 1 | |
| Recruiting |
NCT04484675 -
Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension
|
Phase 4 | |
| Not yet recruiting |
NCT05464238 -
Training in HFpEF-PH
|
N/A | |
| Recruiting |
NCT04808596 -
Pulmonary Hypertension Biorepository and Registry
|
||
| Withdrawn |
NCT04882774 -
Telemonitoring to Treat Group 2 Pulmonary Hypertension
|
Phase 2 |